1. Scrip
  2. >>Therapy Areas

Farxiga Matches Jardiance And Cements SGLT2 Benefits In Heart Failure

AstraZeneca Drug DELIVERs At ESC

 
• By Kevin Grogan

Treatment with Farxiga led to an 18% reduction in a composite endpoint comprising cardiovascular death or worsening heart failure, putting it in the same ballpark as Boehringer Ingelheim and Eli Lilly's Jardiance and its 21% reduction shown in the EMPEROR-Preserved trial last year.

Human heart. 3d illustration.
• Source: Shutterstock

Detailed data from the DELIVER trial of AstraZeneca PLC's Farxiga have demonstrated that the UK major's blockbuster performed roughly on a par with BI and Lilly's fellow SGLT2 inhibitor Jardiance in reducing the risk of cardiovascular death or worsening of heart failure in patients regardless of ejection fraction.

Topline results from the DELIVER Phase III trial released in May already showed that Farxiga/Forxiga (dapagliflozin) reduced the risk of cardiovascular death or worsening heart failure in patients with mildly reduced (HFmrEF) or preserved ejection fraction (HFpEF), defined as left ventricular ejection fraction (LVEF) greater than 40%

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Cardiovascular

More from Therapy Areas

Leo Roars To A Profit In Q1 As Adbry Grows In US

 
• By Kevin Grogan

The Danish firm's atopic dermatitis drug is holding its own despite strong competition from Sanofi/Regeneron’s Dupixent.

Multiple Launches Help Lilly’s Japan Growth

 
• By Ian Haydock

Lilly saw solid growth for its business in Japan last year on the back of several new launches and is building its obesity and Alzheimer's portfolios in the country.

Novo Nordisk Looks To Septerna For Oral Obesity Options

 
• By Mary Jo Laffler

Deal Snapshot: The Danish drugmaker is partnering with GPCR drug discovery expert Septerna to develop multiple small molecules for cardiometabolic targets.